Corcept Therapeutics(CH:HTD)
CH:HTD
Corcept Therapeutics ownership
Corcept Therapeutics (HTD) Ownership - Who Owns Corcept Therapeutics?
0 Followers
Corcept Therapeutics (HTD) Ownership Overview
- 10.53% Insiders
- 15.69% Mutual Funds
- 2.90% Other Institutional Investors
- 19.03% ETFs
- 51.86% Public Companies and Individual Investors
The ownership structure of Corcept Therapeutics (CH:HTD) stock is a mix of institutional, retail, and individual investors. Approximately 37.62% of the company’s stock is owned by Institutional Investors, 10.53% is owned by Insiders, and 51.86% is owned by Public Companies and Individual Investors.
The ownership structure of Corcept Therapeutics (CH:HTD) stock is a mix of institutional, retail, and individual investors. Approximately 37.62% of the company’s stock is owned by Institutional Investors, 10.53% is owned by Insiders, and 51.86% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Aug 27, 2026 | Park Kimberly | $3,269,980 | |
| Aug 17, 2026 | Gary Charles Robb | $1,162,500 | |
| Aug 04, 2026 | Joseph Douglas Lyon | $175,806 | |
| Jun 17, 2026 | David L. Mahoney | $1,690,400 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Royce & Associates Llc | CHF5,796,357 | |
| Dec 31, 2025 | Bridgewater Associates, Lp | CHF9,709,200 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 12,432,023 | Institution | 11.36% | ― |
| Vanguard | 8,445,482 | Institution | 7.72% | ― |
| Vanguard Index Funds | 7,289,126 | Institution | 6.66% | ― |
| Ishares | 6,380,939 | Institution | 5.83% | ― |
| Leonard G. Baker | 5,550,196 | Insider | 5.07% | ― |
| Joseph Belanoff | 2,865,489 | Insider | 2.62% | ― |
| Spdr | 2,038,689 | Institution | 1.86% | ― |
| Fidelity Contrafund | 1,599,462 | Institution | 1.46% | ― |
| James N. Wilson | 1,454,543 | Insider | 1.33% | ― |
| First Trust | 1,179,190 | Institution | 1.08% | ― |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 7,289,126 | Institution | 6.66% | ― |
| Fidelity Contrafund | 1,599,462 | Institution | 1.46% | ― |
| Fidelity Concord Street Trust | 953,156 | Institution | 0.87% | ― |
| Vanguard Tax-managed Funds | 666,455 | Institution | 0.61% | ― |
| Fidelity Salem Street Trust | 612,511 | Institution | 0.56% | ― |
| Fidelity Select Portfolios | 551,746 | Institution | 0.50% | ― |
| Fidelity Rutland Square Trust Ii | 543,395 | Institution | 0.50% | ― |
| Capitol Series Trust | 470,000 | Institution | 0.43% | ― |
| Dfa Investment Dimensions Group Inc | 454,280 | Institution | 0.42% | ― |
| Tiaa-cref Funds | 414,496 | Institution | 0.38% | ― |
FAQ
Who Owns Corcept Therapeutics (CH:HTD)?
According to the latest TipRanks data, approximately 37.62% of the company's stock is held by institutional investors, 10.53% is held by insiders, and 51.86% is held by public companies and individual investors.
What percentage of Corcept Therapeutics (CH:HTD) stock is held by institutional investors?
According to the latest TipRanks data, approximately 37.62% of Corcept Therapeutics (CH:HTD) stock is held by institutional investors: 15.69% by mutual funds, 19.03% by ETFs and 2.90% by other institutional investors.
What percentage of Corcept Therapeutics (CH:HTD) stock is held by retail investors?
According to the latest TipRanks data, approximately 51.86% of Corcept Therapeutics (CH:HTD) stock is held by public companies and individual investors.
Who owns the most shares of Corcept Therapeutics (CH:HTD)?
BlackRock, Inc. owns the most shares of Corcept Therapeutics (CH:HTD).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
